Sean Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sean Zhang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Mohammad R. Salehpour
Department of Radiation Physics The University of Texas M.D. Anderson Cancer Center Houston Texas U.S.A.
2 shared publicationsFiras Mourtada
Department of Radiation Physics, Unit 94, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publicationGloria Beyer
LLC, Medical Physics Services, Tampa, FL, USA
1 shared publicationJoseph Dick
Department of Radiation Physics, Unit 94, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publicationJunfang Gao
The University of Texas M. D. Anderson Cancer Center
1 shared publicationKarl Prado
Department of Radiation Physics The University of Texas M.D. Anderson Cancer Center Houston Texas U.S.A.
1 shared publication
Latest Publications
- 21 April 2011
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Sensors Journal
- Vol. 11 (10) , 2591-2597
Modification of an Implantable MOSFET Dosimeter to Act as a Fiducial Marker
In radiation therapy, the tumor and normal tissue response is highly dependent on accurate absorbed dose delivery to the intended target. Although ex vivo techniques are widely used to improve the accuracy of the dose delivered, it is impossible to verify that the dose has been delivered correctly without measuring the dose within the patient. The Dose Verification System (Sicel Technologies, Inc., Morrisville, NC), which consists of an implantable MOSFET dosimeter and a wireless reader, is currently the only commercial dosimetry system capable of measuring this in situ dose. Since the MOSFET dosimeter is implanted in the patient, it has been suggested that it could be used as not only a dosimeter but also a fiducial marker for image-guided radiation therapy (IGRT) provided that it could be seen on radiographs. Though visible on kilovoltage radiographs, the current design of the dosimeter is not visible on megavoltage radiographs limiting its usefulness in IGRT treatment. In this work, we modified the MOSFET dosimeter to increase its visibility on megavoltage radiographs. We then compared the visibility of the modified dosimeter with that of the commercial (unmodified) dosimeter and a traditional gold fiducial marker in an anthropomorphic phantom on an IGRT system. To ensure that the modification did not affect the dosimeter's ability to measure and transmit dose data, we compared the modified dosimeter's wireless read range, energy dependence, and angular dependence with those of the commercial dosimeter. We conclude that modifying the MOSFET dosimeter increased its visibility without affecting its dosimetric properties, thereby allowing a single implanted device to serve two critical roles in IGRT.
- 21 April 2011
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Sensors Journal
- Vol. 11 (10) , 2591-2597
Modification of an Implantable MOSFET Dosimeter to Act as a Fiducial Marker
In radiation therapy, the tumor and normal tissue response is highly dependent on accurate absorbed dose delivery to the intended target. Although ex vivo techniques are widely used to improve the accuracy of the dose delivered, it is impossible to verify that the dose has been delivered correctly without measuring the dose within the patient. The Dose Verification System (Sicel Technologies, Inc., Morrisville, NC), which consists of an implantable MOSFET dosimeter and a wireless reader, is currently the only commercial dosimetry system capable of measuring this in situ dose. Since the MOSFET dosimeter is implanted in the patient, it has been suggested that it could be used as not only a dosimeter but also a fiducial marker for image-guided radiation therapy (IGRT) provided that it could be seen on radiographs. Though visible on kilovoltage radiographs, the current design of the dosimeter is not visible on megavoltage radiographs limiting its usefulness in IGRT treatment. In this work, we modified the MOSFET dosimeter to increase its visibility on megavoltage radiographs. We then compared the visibility of the modified dosimeter with that of the commercial (unmodified) dosimeter and a traditional gold fiducial marker in an anthropomorphic phantom on an IGRT system. To ensure that the modification did not affect the dosimeter's ability to measure and transmit dose data, we compared the modified dosimeter's wireless read range, energy dependence, and angular dependence with those of the commercial dosimeter. We conclude that modifying the MOSFET dosimeter increased its visibility without affecting its dosimetric properties, thereby allowing a single implanted device to serve two critical roles in IGRT.
- Open Access
- 1 September 2009
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 10 (4) , 177-187
Clinical implementation of electron energy changes of Varian linear accelerators
Modern dual photon energy linear accelerators often come with a few megavoltage electron beams. The megavoltage electron beam has limited range and relative sharp distal falloff in its depth dose curve compared to that of megavoltage photon beam. Its radiation dose is often delivered appositionally to cover the target volume to its distal 90% depth dose (d90), while avoiding the normal ‐ sometimes critical ‐ structure immediately distal to the target. Varian linear accelerators currently offer selected electron beams of 4, 6, 9, 12, 16 and 20 MeV electron beam energies. However, intermediate electron energy is often needed for optimal dose distribution. In this study we investigated electron beam characteristics and implemented two intermediate 7 and 11 MeV electron beams on Varian linear accelerators. Comprehensive tests and measurements indicated the new electron beams met all dosimetry parameter criteria and operational safety standards. Between the two new electron beams and the existing electron beams we were able to provide a choice of electron beams of 4, 6, 7, 9, 11, 12, 16 and 20 MeV electron energies, which had d90 depth between 1.5 cm and 6.0 cm (from 1.5 cm to 4.0 cm in 0.5 cm increments) to meet our clinical needs.PACS number: 87.56.bd.
- 1 September 2009
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 10 (4) , 177-187
Open AccessClinical implementation of electron energy changes of Varian linear accelerators
Modern dual photon energy linear accelerators often come with a few megavoltage electron beams. The megavoltage electron beam has limited range and relative sharp distal falloff in its depth dose curve compared to that of megavoltage photon beam. Its radiation dose is often delivered appositionally to cover the target volume to its distal 90% depth dose (d90), while avoiding the normal ‐ sometimes critical ‐ structure immediately distal to the target. Varian linear accelerators currently offer selected electron beams of 4, 6, 9, 12, 16 and 20 MeV electron beam energies. However, intermediate electron energy is often needed for optimal dose distribution. In this study we investigated electron beam characteristics and implemented two intermediate 7 and 11 MeV electron beams on Varian linear accelerators. Comprehensive tests and measurements indicated the new electron beams met all dosimetry parameter criteria and operational safety standards. Between the two new electron beams and the existing electron beams we were able to provide a choice of electron beams of 4, 6, 7, 9, 11, 12, 16 and 20 MeV electron energies, which had d90 depth between 1.5 cm and 6.0 cm (from 1.5 cm to 4.0 cm in 0.5 cm increments) to meet our clinical needs.PACS number: 87.56.bd.
- 21 April 2009
- Published by Springer Nature in Biomedical Microdevices
- Vol. 11 (4) , 925-933
Quantifying tumor-selective radiation dose enhancements using gold nanoparticles: a monte carlo simulation study
Gold nanoparticles can enhance the biological effective dose of radiation delivered to tumors, but few data exist to quantify this effect. The purpose of this project was to build a Monte Carlo simulation model to study the degree of dose enhancement achievable with gold nanoparticles. A Monte Carlo simulation model was first built using Geant4 code. An Ir-192 brachytherapy source in a water phantom was simulated and the calculation model was first validated against previously published data. We then introduced up to 1013 gold nanospheres per cm3 into the water phantom and examined their dose enhancement effect. We compared this enhancement against a gold-water mixture model that has been previously used to attempt to quantify nanoparticle dose enhancement. In our benchmark test, dose-rate constant, radial dose function, and two-dimensional anisotropy function calculated with our model were within 2% of those reported previously. Using our simulation model we found that the radiation dose was enhanced up to 60% with 1013 gold nanospheres per cm3 (9.6% by weight) in a water phantom selectively around the nanospheres. The comparison study indicated that our model more accurately calculated the dose enhancement effect and that previous methodologies overestimated the dose enhancement up to 16%. Monte Carlo calculations demonstrate that biologically-relevant radiation dose enhancement can be achieved with the use of gold nanospheres. Selective tumor labeling with gold nanospheres may be a strategy for clinically enhancing radiation effects.
- 21 April 2009
- Published by Springer Nature in Biomedical Microdevices
- Vol. 11 (4) , 925-933
Quantifying tumor-selective radiation dose enhancements using gold nanoparticles: a monte carlo simulation study
Gold nanoparticles can enhance the biological effective dose of radiation delivered to tumors, but few data exist to quantify this effect. The purpose of this project was to build a Monte Carlo simulation model to study the degree of dose enhancement achievable with gold nanoparticles. A Monte Carlo simulation model was first built using Geant4 code. An Ir-192 brachytherapy source in a water phantom was simulated and the calculation model was first validated against previously published data. We then introduced up to 1013 gold nanospheres per cm3 into the water phantom and examined their dose enhancement effect. We compared this enhancement against a gold-water mixture model that has been previously used to attempt to quantify nanoparticle dose enhancement. In our benchmark test, dose-rate constant, radial dose function, and two-dimensional anisotropy function calculated with our model were within 2% of those reported previously. Using our simulation model we found that the radiation dose was enhanced up to 60% with 1013 gold nanospheres per cm3 (9.6% by weight) in a water phantom selectively around the nanospheres. The comparison study indicated that our model more accurately calculated the dose enhancement effect and that previous methodologies overestimated the dose enhancement up to 16%. Monte Carlo calculations demonstrate that biologically-relevant radiation dose enhancement can be achieved with the use of gold nanospheres. Selective tumor labeling with gold nanospheres may be a strategy for clinically enhancing radiation effects.